Foghorn Therapeutics Inc.FHTXNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank57
3Y CAGR-6.8%
5Y CAGR+8.2%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-6.8%/yr
vs +49.4%/yr prior
5Y CAGR
+8.2%/yr
Recent deceleration
Acceleration
-56.2pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
2 yr
Consecutive declineStable
PeriodValueYoY Change
2025$85.47M-9.6%
2024$94.53M-13.8%
2023$109.69M+3.9%
2022$105.62M+31.5%
2021$80.33M+39.2%
2020$57.72M+30.1%
2019$44.36M+109.0%
2018$21.23M-